Careers Investor Relations Education & Training Portal Logins CONTACT PRODUCTS & SERVICES SPECIALTY EXPERTISE CUSTOMER SUPPORT ABOUT US Who We Are Our Inspiration Locations Corporate Social Responsibility Humane Care Initiative Eureka Science Community Investor Relations News & Events Careers News & Events News & Events Featured Stories Media Coverage Press Releases Conferences Press Resources Media Coverage James Foster Interview on Mad Money with Jim Cramer 08/11/2015 In this interview, James Foster, chairman and CEO of Charles River Laboratories, discusses the reopening of the Shrewsbury, Massachusetts facility and Charles River’s partnership with AstraZeneca. Will This Multi-Million Dollar Purchase Pay off for This Biotech? 07/10/2015 Charles River has announced a $212 million purchase of British company Celsis International. The company specializes in providing systems that are used to detect harmful contaminants in substances ranging from prescription drugs to consumer beverages. Charles River buys Celsis for $212M 07/10/2015 The acquisition of Celsis International Ltd. complements Charles River Endotoxin and Microbial Detection’s (EMD) position as a leading provider of rapid endotoxin testing and bacterial identification for biopharmaceutical manufacturing, and creates the most comprehensive solution for rapid quality control testing of biopharmaceutical and consumer products. Charles River to Acquire Celsis International for $212M in Cash 07/09/2015 Charles River announced that it has entered into a definitive agreement to acquire Celsis International Ltd. for $212 million in cash, subject to customary closing adjustments. Charles River spends $212M to Beef Up its Microbial Testing 07/09/2015 Charles River is absorbing Celsis, a Chicago-headquartered company that tests drugs and consumer products for contamination. Celsis works with pharma, beauty companies and the food industry, touting itself as a provider of rapid testing systems that allow clients to quickly get their products onto the market. Why Charles River Labs spent $212M on a Bacteria Detection Company 07/09/2015 Charles River Labs announced Thursday that it had signed an agreement to acquire the bacteria detection company Celsis International Ltd. for $212 million. This acquisition will strengthen the Wilmington company’s market position in testing the safety of drugs and consumer products. From Crab to Lab 06/23/2015 The Atlantic horseshoe crab and Charles River have mutually benefitted from one another for the last thirty years. In a recent article, John Dubczak, General Manager of Endotoxin and Microbial Detection, spoke about the value of the horseshoe crab and the efforts that Charles River has undergone in order to protect and preserve this natural resource. The Rise of Syngeneic Models in Cancer Immunotherapy 06/17/2015 With cancer immunotherapy becoming a major focus of oncology research over the past several years, the next blockbuster drug will likely target the immune system. By exploiting model systems, such as syngeneic tumors, and identifying the next major variable associated with immunologically driven elimination of tumor cells, the promise of new immunotherapies can be realized. The New Paradigm in Cardiac Toxicity Testing 06/04/2015 The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative came about after the realization that the current cardiac toxicity testing paradigm is too conservative, keeping potentially beneficial drugs off the market and away from patients who need them. At the same time, current methods are relatively poor predictors of drug-induced cardiac arrhythmias. Essential Instruments for Open-Access Environment 06/02/2015 Ultra high-performance liquid chromatography (UHPLC) can increase data reproducibility and instrument capacity in the medicinal chemistry laboratory setting. DISPLAYING RESULTS 1-10 (OF 62) |< < 1 - 2 - 3 - 4 - 5 - 6 - 7 > >| Contact Us Our experts are available to answer any questions or discuss a quote. From: North America Europe Asia Other Call us at: 1.877.CRIVER.1 (1.877.274.8371) EMAIL US Subscribe to our mailing list to learn about our latest advances: SUBSCRIBE » Careers Press Resources Investor Relations Legal Compliance Policies Connect with Us: RSS Twitter Facebook LinkedIn YouTube © 2021 Charles River Laboratories International, Inc. Legal Terms & Conditions Privacy Policy Safe Harbor Privacy Policy Products & Services Research Models & Services Discovery Services Preclinical Services Biologics Testing Solutions Endotoxin Detection & Microbial Identification Avian Vaccine Services Chemicals, Agro & Vet Therapeutic Areas Cardiovascular Central Nervous System Inflammation Metabolic Disease Musculoskeletal Disease Oncology Ophthalmology Respiratory Disease Contact Us Locations Initiate a Project News & Events What's New at Charles River Education & Training Eureka Science Community